McClellan’s Policy Clout Creates Big Shoes To Fill At FDA
Executive Summary
The planned reorganization of FDA following Commissioner Mark McClellan's departure reflects an emphasis on interactions with Capitol Hill and the Administration
You may also be interested in...
FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA is announcing a leadership succession plan for the Office of Policy & Planning ahead of the impending retirement of Associate Commissioner William Hubbard
FDA adds legislative staffer
House Commerce Committee staffer Patrick Ronan is joining FDA as assistant commissioner for legislation. He will report to Associate Commissioner for Legislation Amit Sachdev, who is serving as acting deputy commissioner for policy. Sachdev is playing an increased role in policy coordination with Capitol Hill and the Administration following former FDA Commissioner McClellan's departure to CMS (1"The Pink Sheet" March 15, 2004, p. 8). Before joining the Commerce Committee at the beginning of 2003, Ronan was director of government relations for the Biotechnology Industry Organization...
FDA adds legislative staffer
House Commerce Committee staffer Patrick Ronan is joining FDA as assistant commissioner for legislation. He will report to Associate Commissioner for Legislation Amit Sachdev, who is serving as acting deputy commissioner for policy. Sachdev is playing an increased role in policy coordination with Capitol Hill and the Administration following former FDA Commissioner McClellan's departure to CMS (1"The Pink Sheet" March 15, 2004, p. 8). Before joining the Commerce Committee at the beginning of 2003, Ronan was director of government relations for the Biotechnology Industry Organization...